What RYZODEG FlexTouch Treats: Main Uses and Benefits

RYZODEG FlexTouch is used to assist in the management of glycemic control in patients with Diabetes Mellitus, covering both Type 1 and Type 2. It is indicated for the long-term, comprehensive management of chronic hyperglycemia. This product is commonly used to help with symptoms related to systemic imbalance in glucose management in both adults and relevant pediatric patient groups.

---

The medication is applied to manage the symptomatic cluster of dual glucose elevation. It is relevant for easing symptoms associated with systemic imbalance between meals and overnight, and helps address acute post-meal glucose spikes that occur after eating. This dual action contributes to easing the overall symptom load related to fluctuating glucose levels.

This combination generally may assist in providing a simplified treatment regimen to patients requiring both foundational and mealtime insulin coverage. It helps ease the logistical burden by combining the two necessary components, which supports general well-being during symptomatic phases and assists with maintaining functional stability in the patient's day-to-day routine.

---

Quick Fact: Relief for Dual Glucose Control
Conditions Managed	Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Symptom Patterns Addressed	Overnight high blood sugar and post-meal glucose spikes
Patient Benefit	Contributes to easing the overall symptom load and supports improved comfort

Regulatory References

1. European Medicines Agency

RYZODEG FlexTouch is approved for use in patients with diabetes mellitus, but official regulatory documents specify clear eligibility and non-eligibility requirements.

Contraindicated and Non-Eligible Populations

Classification	Who Must Not Use (Contraindicated/Not Recommended)
Absolute Contraindication	Patients experiencing hypoglycemia (low blood sugar)
	Patients with known hypersensitivity or allergy to insulin degludec, insulin aspart, or any excipients
Use Not Recommended	For the treatment of diabetic ketoacidosis
	Pediatric patients requiring a total daily dose of less than 5 units (FDA limitation)

---

Eligibility by Age and Special Population

Population Group	Eligibility Status (Regulatory Basis)
Minimum Age (FDA)	ge 1 year of age
Minimum Age (EMA)	ge 2 years of age
Renal/Hepatic Impairment	Use is permitted, but requires intensified blood glucose monitoring and individual dose adjustment.
Pregnancy/Lactation	Use is generally permitted, though intensified monitoring is recommended during pregnancy, and dose adjustments may be needed while breastfeeding.

These official statements define who is eligible to use the medicine and who is formally excluded, with age limits varying slightly by region (e.g., ge 1 year versus ge 2 years), and clear restrictions against use during acute hypoglycemic episodes or diabetic ketoacidosis.

Interactions with other medicines and products

Regulatory labeling documents provide specific classifications for medicinal products and substances that interact with RYZODEG FlexTouch, primarily by modifying its effect on blood glucose levels.

Pharmacodynamic Effects and Restrictions

Interaction Type	Interacting Agents / Classes (Official Documentation)
Increased Hypoglycemia Risk	Other antidiabetic agents, ACE inhibitors, ARBs, MAOIs, Salicylates, Somatostatin analogs, Disopyramide, Fluoxetine.
Decreased Efficacy (Hyperglycemia)	Corticosteroids, Diuretics (e.g., Thiazides), Atypical Antipsychotics, HIV Protease Inhibitors.
Masking of Hypoglycemia Signs	Anti-Adrenergic Drugs (e.g., Beta-blockers, Reserpine).
Systemic Risk Interaction	Thiazolidinediones (e.g., Pioglitazone), associated with an official warning for dose-related fluid retention that may lead to or worsen congestive heart failure.

Official Combination Constraints

The most prominent regulatory restriction is the procedural constraint that the medicine must not be diluted or mixed with any other insulin product or solution. No required time separation windows between RYZODEG FlexTouch and co-administered medicines are specified in the regulatory labeling.

Substance and Population Notes

Alcohol (Ethanol) is officially documented as a substance that may either potentiate or reduce the medicine's glucose-lowering effect. For patients with Renal impairment or Hepatic impairment, the blood glucose-lowering effect may be increased due to reduced clearance, and use is cautioned in patients with risk for Hypokalemia.

RYZODEG is a co-formulation of two distinct insulin analogues: insulin degludec (IDeg) and insulin aspart (IAsp). Both analogues function as agonists at the insulin receptor (IR) complex, primarily on target tissues such as skeletal muscle, adipocytes, and hepatocytes. Binding to the IR alpha-subunit induces a conformational change, activating the tyrosine kinase intrinsic to the beta-subunit. This activation initiates a molecular signaling cascade, including phosphorylation of Insulin Receptor Substrates (IRS) and subsequent activation of PI3K/Akt pathways.

Downstream consequences include the translocation of Glucose Transporter type 4 (GLUT4) vesicles to the cell membrane in muscle and fat, facilitating glucose uptake. The hepatic pathway is modified by the inhibition of gluconeogenesis and glycogenolysis, which suppresses endogenous glucose production.

IDeg forms soluble multihexamers upon subcutaneous injection, creating a drug depot from which monomers are slowly released, resulting in a sustained systemic physiological effect. IAsp, due to a proline-to-aspartic acid substitution at B28, rapidly dissociates into monomers, ensuring rapid systemic absorption and a faster modulation of postprandial glucose metabolism.

Method of Administration

RYZODEG FlexTouch is a pre-filled pen designed for subcutaneous injection. This medication is typically administered once or twice daily with the main meal(s). The injection is delivered into the fatty tissue under the skin, with common injection sites including the abdominal wall, the upper arm, or the thighs.

Site Rotation

To manage the condition of the skin at the injection sites, it is important to rotate the specific point of injection within the chosen body area. Using a different spot for each administration helps maintain the health of the subcutaneous tissue.

Device Design

The FlexTouch device is a multi-dose, disposable pen. It is engineered to allow for dose selection in increments. The mechanism is designed so that the push-button does not extend during the injection process, which assists in the delivery of the medication.

Preparation and Handling

Before use, the medication should be inspected to ensure the solution is clear and colorless. If the liquid appears cloudy or contains particles, it should not be used. The device is intended for use with compatible single-use needles.

Storage and Maintenance

The pen should be stored according to specific temperature requirements to maintain its stability. It is important to remove the needle after every injection and store the pen without a needle attached to prevent leakage or contamination. The pen cap should be replaced after use to protect the medication from light.

RYZODEG FlexTouch: Recent Clinical Evidence

---

Evidence for use in Type 2 Diabetes Mellitus

The clinical evaluation was studied for adults with Type 2 Diabetes, utilizing Randomized Controlled Trials (RCTs) and Observational Studies. Research examined effects on the long-term glycemic biomarker, Glycated Hemoglobin (HbA1c), alongside changes in fasting and post-meal blood sugar. Findings describe patterns observed in which blood sugar control findings were observed in a manner consistent with established comparator insulins. Specific trials reported patterns in the occurrence rate of nocturnal low blood sugar that were observed in some studies to be distinct from those recorded with certain older-generation comparators. The evidence quality is based on the volume of controlled research.

---

Evidence for use in Type 1 Diabetes Mellitus

Research for Type 1 Diabetes was evaluated in controlled clinical trials focused on adults and pediatric patients. Studies monitored outcomes related to systemic imbalance regarding HbA1c and fasting blood sugar. Findings for this population were observed in a manner consistent with those receiving other basal insulin regimens. Sample sizes were modest, and research is less extensive than the data available for Type 2 Diabetes.

---

Evidence in Special Populations

Research has explored the use of the medicine in elderly patients (≥ 65 years) and the pediatric population (children and adolescents from 1 year of age). Studies monitored blood sugar stability in these cohorts. While findings indicate patterns related to glycemic control that appear to be similar to adult populations, the data for certain groups remain insufficient. Certainty remains low for patients under 2 years of age.

---

Durability of Glycemic Control and Long-Term Follow-up

The majority of the controlled clinical trials utilized follow-up durations that were limited, primarily spanning around six months (26 weeks). This means that research provides insight into short-term changes. Long-term effects are not fully established by controlled evidence, and there is limited information regarding the sustained stability of blood sugar levels beyond intermediate durations.

---

What is still uncertain about RYZODEG FlexTouch

Comparative evidence is lacking for direct head-to-head trials against all newer-generation basal/prandial insulin combinations. Furthermore, data for certain groups remain insufficient, especially for specific pediatric subgroups. Research provides context but not individual predictions about how a person may respond.

Key Studies & References

1. Real-world effectiveness of insulin degludec/insulin aspart in type 2 diabetes mellitus: A systematic review.

Common questions about RYZODEG FlexTouch (FAQ)

---

Q: How quickly does RYZODEG FlexTouch start to work after an injection?

According to official product information, RYZODEG FlexTouch is a combination insulin product. It contains insulin aspart, which is a rapid-acting component described in regulatory documents as ensuring rapid absorption and a quick start of action. The rapid component is noted to address the rise in blood sugar that typically follows a meal.

Q: How long does the effect of RYZODEG FlexTouch last?

Official product information indicates that the insulin degludec component is described as having an ultra-long duration of action, with an effect that may last for more than 24 hours.

Q: Do people typically experience weight gain when starting RYZODEG?

Regulatory documents describe weight gain as a potential side effect associated with insulin therapy. Clinical trials for Type 2 diabetes patients, for example, reported an average weight gain of approximately 1.6 kg during the studies.

Q: How many units of insulin can the RYZODEG FlexTouch pen hold?

The RYZODEG FlexTouch pen is a pre-filled device containing a 3 mL cartridge, which is equivalent to 300 U of the insulin combination. Regulatory documents state the pen is designed to deliver insulin in one-unit increments, allowing a maximum dose of 80 units in a single injection.

Q: What happens if I miss a scheduled dose of RYZODEG FlexTouch?

Regulatory guidance states that if a dose is missed, it should be taken with the next main meal of that day, and the usual dosing schedule should be resumed thereafter. Official guidance indicates that patients should not take an extra dose or increase the amount of a subsequent dose to compensate for the missed dose.

Q: What are the official warnings or precautions listed for RYZODEG FlexTouch?

Official warnings include the risks of hypoglycemia (low blood sugar) and hypokalemia (low potassium levels). A specific warning is issued regarding the potential for fluid retention that may lead to or worsen heart failure when RYZODEG is used with certain other medications (Thiazolidinediones). Official warnings emphasize that the pen should not be shared between patients.

Q: Why is RYZODEG FlexTouch sometimes prescribed instead of an oral diabetes medicine?

RYZODEG is indicated for use in diabetes when insulin therapy is required. It is a dual-acting product that provides both basal and mealtime insulin coverage, which may be appropriate when oral medications alone are insufficient to achieve prescribed glycemic control, according to official product information.

Q: What research is available on using RYZODEG in combination with other diabetes treatments?

Regulatory documents state RYZODEG has been studied for use in combination with oral anti-diabetic medicinal products (such as Metformin) for Type 2 diabetes. It has also been studied alongside other short- or rapid-acting insulin given at different mealtimes, particularly in clinical trials for Type 1 diabetes.

Q: Can RYZODEG FlexTouch be carried in hand luggage when traveling by air?

Official storage information requires the product to be protected from freezing. When traveling by air, to avoid the risk of freezing, which can occur in the cargo hold, carrying insulin in a carry-on bag is often suggested.

Q: Is RYZODEG FlexTouch considered a long-acting insulin?

RYZODEG FlexTouch is classified in regulatory documents as a soluble insulin product that is dual-acting. It is a combination of two distinct insulin molecules: an ultra-long-acting basal insulin (insulin degludec) and a rapid-acting mealtime insulin (insulin aspart).

Q: Does using RYZODEG FlexTouch affect the kidneys or liver?

The regulatory label notes that the blood glucose-lowering effect may be increased in patients with renal (kidney) or hepatic (liver) impairment due to reduced clearance of the insulin. For these patients, intensified blood glucose monitoring and careful dose adjustment are required.

Q: Do certain diets or foods change how RYZODEG FlexTouch works?

Regulatory documents require RYZODEG to be taken with a main meal to effectively manage post-meal blood sugar. Official product information notes that the need to adjust dosing and monitoring is a standard precaution in the event of changed meal patterns.

Q: What is the risk of having a serious complication like ketoacidosis while using RYZODEG?

RYZODEG is not indicated for the treatment of diabetic ketoacidosis ( DKA), which is a serious, acute complication of high blood sugar. Although this treatment is part of a plan to help prevent DKA, regulatory information notes that poor blood sugar control can still occur.

Q: How is RYZODEG FlexTouch different from just taking separate long-acting and fast-acting insulins?

RYZODEG is a co-formulation, meaning it combines both the ultra-long-acting basal insulin and the rapid-acting mealtime insulin into a single preparation. According to regulatory information, this provides an alternative to managing blood sugar with separate basal and bolus injections or other premixed insulins.

Q: Can people with heart problems use RYZODEG FlexTouch?

Official warnings caution that there is a risk of fluid retention and potential worsening of congestive heart failure when RYZODEG is used simultaneously with certain TZD medicines.

Q: What is the significance of the 'FlexTouch' name for the delivery device?

The FlexTouch pen is the designated delivery system for the medicine and is described in official product information as a pre-filled disposable pen. This device is engineered to facilitate ease of use for the injection process.

Q: How is the dose measured on the RYZODEG FlexTouch pen?

The FlexTouch pen is the specific delivery system for the medicine. According to official instructions, the pen uses a dial-a-dose mechanism and is designed to deliver the insulin in one-unit increments.

Q: Why is the insulin combination in RYZODEG called a 'co-formulation'?

The term is used because RYZODEG is a soluble insulin product that combines two distinct insulin molecules, insulin degludec and insulin aspart, in a fixed ratio (70/30) within the same liquid preparation. Official documents describe this fixed-ratio blend as allowing for the combined delivery of both types of insulin with a single injection.

Q: Are there any special considerations for people who drive or operate machinery while using RYZODEG?

Official product information states that a person's ability to concentrate and react may be impaired by an episode of hypoglycemia (very low blood sugar). Because hypoglycemia is a very common side effect of insulin use, this risk should be considered in situations like driving or operating machinery.

Q: Is RYZODEG FlexTouch available in different strengths?

Official regulatory documents confirm that RYZODEG is available as a solution for injection at a single strength: 100 U/mL of insulin degludec/insulin aspart (in a 70/30 ratio).

How to Store and Dispose of RYZODEG FlexTouch

Storage and disposal must strictly adhere to regulatory requirements to maintain product stability and ensure safe handling.

Storage Conditions

Unopened RYZODEG FlexTouch pens must be stored in a refrigerator at a temperature between 2 C and 8 C (36 F and 46 F) in the original carton to protect from light. The product must not be frozen; pens that have been frozen must be discarded.

Once opened or put into use, the pen may be stored for a maximum of 28 days (four weeks) at room temperature (below 30 C or 86 F) or in a refrigerator. The pen cap must remain on when not in use, and the pen must not be stored with a needle attached.

Disposal and Safety

The pen must be stored out of the reach of children. Unused medicinal product, expired pens, and associated waste must be disposed of in accordance with local regulatory requirements. The product should not be disposed of via household waste or wastewater, and used needles must be removed and discarded after each injection.